Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Graham-Field

This article was originally published in The Gray Sheet

Executive Summary

"Debtor-in-possession" credit facility for up to $38.8 mil. is secured following the filing of a voluntary Chapter 11 bankruptcy petition in Delaware federal court. The financing will provide the medical/surgical supply maker and distributor with sufficient liquidity to pay suppliers for "post-petition" goods and services, meet payroll, and carry it through completion of its debt restructuring, the firm says. The bankruptcy petition coincides with the resignations of John McGregor as president and CEO, and of Robert Gluck as chief financial officer. David Hilton was named to replace McGregor. Hilton is known as a turn-around specialist and formerly headed J.E. Morgan Knitting Mills. Rothschild, Inc. has been retained to provide investment-banking services

You may also be interested in...



Graham-Field Health Products, Inc.

Replacement $35 mil. "debtor-in-possession" financing agreement with Congress Financial Corporation closes April 17. The new financing arrangement replaces the current DIP loan serviced by IBJ Whitehall Business Credit Corporation, secured following a Chapter 11 bankruptcy filing in Delaware federal court, and includes more favorable terms (1"The Gray Sheet" Jan. 10, p. 10). "It is obvious that the financial community has strong faith in the company's ability to emerge from its Chapter 11 voluntary bankruptcy position as an on-going concern," CEO David Hilton commented

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel